Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia
Schizophr Res
.
2024 May:267:239-246.
doi: 10.1016/j.schres.2024.03.052.
Epub 2024 Apr 5.
Authors
M Opler
1
,
S Negash
2
,
K Tatsumi
2
,
C Liu
2
,
M Komaroff
3
,
G Capodilupo
2
,
M Hasebe
4
,
B Echevarria
2
,
R Blattner
2
,
L Citrome
5
Affiliations
1
WCG Inc., New York, NY, USA. Electronic address: mark.opler@panss.org.
2
WCG Inc., New York, NY, USA.
3
Noven Pharmaceuticals, Inc., Jersey City, NJ, USA.
4
Hisamitsu Pharmaceutical Co., Inc., Tosu, Japan.
5
New York Medical College, New York, NY, USA.
PMID:
38581826
DOI:
10.1016/j.schres.2024.03.052
No abstract available
Publication types
Letter
MeSH terms
Antipsychotic Agents / therapeutic use
Data Accuracy
Data Interpretation, Statistical
Humans
Psychiatric Status Rating Scales / standards
Schizophrenia* / diagnosis